Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EstechPharma In Talks With German Company For MRI Contrast Medium Agents; Korean API Makers Struggle For Global Foothold

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's active pharmaceutical ingredient company EstechPharma is currently in talks with a German-based multinational company, likely Bayer Schering Pharma, to sell its two generic MRI contrast medium products

You may also be interested in...



Korea’s Dong-A Wins WHO Prequalification For TB Generic Of Lilly’s Seromycin As Firm Moves Up Value Chain

WHO prequalification clears path for Korea’s Dong-A to move from an API supplier of cycloserine to an exporter of finished products.

Italy's Bracco Taps Korea To Boost Sales Of Medical Contrast Mediums; Takes On Bayer Schering And GE Healthcare

SEOUL - Italy's Bracco has opened a Korean unit as part of its efforts to increase share for its medical contrast mediums in a market already dominated by Bayer Schering Pharma and GE Healthcare

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

SC075913

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel